RecruitingNot ApplicableNCT07414342

Safety and Efficacy of the RENATUS® Transcatheter Aortic Valve System for the Treatment of Severe Aortic Stenosis

Sponsor

Beijing Balance Medical Technology Co., Ltd

Enrollment

800 participants

Start Date

Feb 1, 2026

Study Type

INTERVENTIONAL

Conditions

Severe aortic stenosis

Summary

This study is a prospective, non-randomized, observational, post-market follow-up trial designed to evaluate the safety and efficacy of the RENATUS® Transcatheter Aortic Valve System for the treatment of severe aortic stenosis.

Eligibility

Min Age: 60 YearsMax Age: 100 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called RENATUS® TAVR for people with severe aortic stenosis. The study is currently recruiting participants at 4 locations. People eligible for this study include aged 60 Years to 100 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.